Experimental MS drug bests approved therapy in cutting relapses in 2 trials
That's according to top-line data — the studies' first results — announced by remibrutinib's developer Novartis, sponsor of the pair of Phase 3 […]
Useful takeaways from this story.
That's according to top-line data — the studies' first results — announced by remibrutinib's developer Novartis, sponsor of the pair of Phase 3 […]
An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials involving people with...
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
That's according to top-line data — the studies' first results — announced by remibrutinib's developer Novartis, sponsor of the pair of Phase 3 […] An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials involving people with relapsing forms of multiple sclerosis (MS).
Details worth keeping
An experimental oral drug called remibrutinib outperformed the approved therapy Aubagio (teriflunomide) in reducing disease flare rates in two large, late-stage clinical trials involving people with relapsing forms of multiple sclerosis (MS).
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.